A Phase 4 interventional study of Intrathecal morphine injection and EXPAREL in Pain, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 5 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-26.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Liposomal Bupivacaine in Pain — 5 open to participants now, 5 under way, 2 of them phase 3. Liposomal Bupivacaine · Pain.
Among the 36 studies testing Liposomal Bupivacaine in Pain, this one is the 30th largest by enrollment, is one of 6 that started in 2015, is one of 22 in phase 4, and was the 12th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →5 of the 36 studies testing Liposomal Bupivacaine in Pain are open now, in 2 countries. Recruiting first, the newest first:
Children's Hospital of Orange County · Sites in United States
Ages 7–17 · Healthy volunteers
Jessyka Lighthall · Sites in United States
Ages 18–99 · Healthy volunteers
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Tongliao City People's Hospital · Sites in China
Ages 18–60
By country, each count listing its studies:
Liposomal Bupivacaine: first FDA approval 2011 (EXPAREL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 8 · Phase 4 22
First in 2013; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 60 across the 36 interventional studies. Of the 24 that completed or were terminated, 21 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
29 studies in Pain by Pacira BioSciences, Inc.: none open now, none under way, none of them phase 3. Of 29 finished, 26 (90%) have results posted.
Among the 29 studies in Pain by Pacira BioSciences, Inc., this one is the 26th largest by enrollment, is one of 4 that started in 2015, is one of 6 in phase 4, and was the 16th registered.
Pacira BioSciences, Inc.’s Pain studies by the year they started, since 2007.
4 of the studies testing Liposomal Bupivacaine in Pain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05964868Phase 3Jessyka LighthallEfficacy of Liposomal Bupivacaine Post Septorhinoplasty | 2026-12 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07097493Wake Forest University Health SciencesLiposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty | 2027-06 |
| NCT07795203Tongliao City People's HospitalLiposomal Bupivacaine vs Ropivacaine for Post-hemorrhoidectomy Analgesia | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing Liposomal Bupivacaine in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pacira BioSciences, Inc.’s 29 in Pain:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, multicenter, open-label study evaluating EXPAREL infiltration into the transversus abdominis plane (TAP) after bupivacaine hydrochloride (HCl) spinal anesthesia in subjects undergoing elective Cesarean section (C-section).
There will be two groups of subjects with approximately 40 subjects per group. Prior to the C-section, all subjects will receive single-shot spinal anesthesia (1.5 mL bupivacaine HCl 0.75% with dextrose 8.25%). Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered. Subjects in Group 2 (EXPAREL/TAP) will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previous participating in an EXPAREL study.
The subject will be withdrawn from the study if she meets the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
Drug: Intrathecal morphine injection
Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
Drug: EXPAREL
0.2 mg
Also known as: Duramorph
266 mg
Also known as: Bupivacaine liposome injectable suspension
Total Postsurgical Narcotic Consumption in Morphine Equivalents
Outcome measure data refer to 7 participants who received rescue medication
Time frame: Through 72 hours postdose
Total Postsurgical Narcotic Consumption in Morphine Equivalents
Outcome measure data refer to 6 participants who received rescue medication
Time frame: Through 24 hours
Total Postsurgical Narcotic Consumption in Morphine Equivalents
Outcome measure data refer to 7 participants who received rescue medication
Time frame: Through 48 hours
| Milestone | Standard of Care | EXPAREL/TAP |
|---|---|---|
| Started | 12 | 0 |
| Completed | 10 | 0 |
| Not completed | 2 | 0 |
Outcome measure data refer to 7 participants who received rescue medication
| MUEs | Standard of Care | EXPAREL/TAP |
|---|---|---|
| Total Postsurgical Narcotic Consumption in Morphine Equivalents | 6.1 ± 3.67 | — |
Outcome measure data refer to 6 participants who received rescue medication
| MUEs | Standard of Care | EXPAREL/TAP |
|---|---|---|
| Total Postsurgical Narcotic Consumption in Morphine Equivalents | 4.9 ± 2.01 | — |
Outcome measure data refer to 7 participants who received rescue medication
| MUEs | Standard of Care | EXPAREL/TAP |
|---|---|---|
| Total Postsurgical Narcotic Consumption in Morphine Equivalents | 6.1 ± 3.67 | — |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care | — | 0/12 (0%) | 2/12 (16.7%) |
| EXPAREL/TAP | — | — | — |
| Event | Standard of Care | EXPAREL/TAP |
|---|---|---|
| oral herpesInfections and infestations | 1/12 | — |
| bladder injuryInjury, poisoning and procedural complications | 1/12 | — |
The study was terminated due to slow enrollment after 12 subjects were assigned to Group 1 (Standard of Care/Duramorph). As no subjects were enrolled into Group 2 (EXPAREL/TAP), no conclusions can be drawn regarding the study endpoints.
| Age, Categorical(Participants) | Standard of Care | EXPAREL/TAP | Total |
|---|---|---|---|
| <=18 years | 0 | — | 0 |
| Between 18 and 65 years | 12 | — | 12 |
| >=65 years | 0 | — | 0 |
| Age, Continuous(years) | Standard of Care | EXPAREL/TAP | Total |
|---|---|---|---|
| Mean | 32.2 ± 4.71 | — | 32.2 ± 4.71 |
| Sex/Gender, Customized(participants) | Standard of Care | EXPAREL/TAP | Total |
|---|---|---|---|
| Female | 12 | — | 12 |
| Male | 0 | — | 0 |
| Region of Enrollment(participants) | Standard of Care | EXPAREL/TAP | Total |
|---|---|---|---|
| United States | 12 | — | 12 |
The record gives a start of May 2015, a primary completion of Jun 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine